Skip to content
Poster

Proof-of-concept testing of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Background & aim:

The long-acting glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved for the treatment of type 2 diabetes and obesity. Recently, semaglutide has been reported to improve liver histopathological outcomes in patients with metabolic dysfunction-associated steatohepatitis
(MASH) and fibrosis (Phase 2b: Newsome et al., NEJM, 2020; Phase 3: ESSENCE). We have recently showed therapeutic efficacy during longer-term semaglutide intervention in the translational GAN dietinduced obese (DIO) mouse model of fibrosing MASH (Møllerhøj et al. Clin Transl Sci, 2022). The present study aimed to evaluate semaglutide treatment for 6 weeks proof-of-concept testing in the GAN DIO-MASH mouse model.

Subjects
GAN DIO-MASH mouseMouseBody weightBlood biochemistryBioinformaticsMetabolic dysfunction-associated steatohepatitisGLP-1 receptorImage analysisImmunohistochemistry (IHC)Liver biopsyLiver morphometryNext-generation sequencingRNA sequencingSemaglutide

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top